EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types

Jorge D Oldan, Anurag Anugu, Md Zobaer Islam, Alireza Amindarolzarbi, Rudolf A Werner, Martin G Pomper, Lilja B Solnes, Frankis Almaguel, Stergios Moschos, Benjamin L Viglianti, Steven P Rowe

Diagnostic and Interventional Imaging · 2025

DOI: 10.1016/j.diii.2025.07.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostic and Interventional Imaging, 2025. Verfasst von Jorge D Oldan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of North Carolina, Chapel Hill, NC, 27599, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Neoplasms, Theranostic Nanomedicine, Molecular Targeted Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To date, prospective, pivotal clinical trials in the theranostic space have focused on specific disease states. Those include leveraging positron emission tomography (PET) findings to optimize the second-line use of 177Lu-DOTATATE in patients with metastatic and progressive neuroendocrine tumors or the use of prostate-specific membrane antigen (PSMA) PET findings to select patients with metastatic castration-resistant prostate cancer for treatment with 177Lu-PSMA-617. However, we are entering an era where a broader understanding of the expression patterns of a wide variety of targets is beginning to be understood. As an example, PSMA PET has shown potential utility in the imaging of clear cell renal cell carcinoma and other malignancies with high rates of neovascularity. Many of the theranostic agents in the pipeline are designed to bind against "pan-cancer" targets such as fibrinogen-activating protein or the C-X-C motif chemokine receptor 4, or targets that become over-expressed in a broad variety of cancer states, such as those that target carbonic anhydrase IX. Artificial intelligence methods will assist us in appropriately selecting patients and in delivering predictive and prognostic imaging biomarkers. Given the wide potential applicability of emerging theranostic agents, it will be incumbent upon the field to carefully design clinical trials that will lead to regulatory approvals that will, in turn, permit broad use across a number of cancer types. In our future clinical practices, we will evolve to leverage precision medicine to identify target expression and deliver appropriate theranostic agents that are not limited to a specific cell of origin or disease state.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceNeoplasmsTheranostic NanomedicineMolecular Targeted TherapyHumansPrecision Medicine

Stichwörter der Autor:innen

Fibrinogen-activating proteinProstate-specific membrane antigenRadioligand therapyTheranostics

Autor:innen und Institutionen

  • Department of Radiology, University of North Carolina, Chapel Hill, NC, 27599, USA.
  • Duke University, Durham, NC, 27708, USA.
  • Department of Radiology, University of Texas Southwestern Medical Cetner, Dallas, TX, 75390, USA.
  • Nuclear Medicine, University of Maryland, Baltimore, MD, 21250, USA.
  • Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21234, USA.

Förderung

  • NIBIB NIH HHS

Zitieren

APA

Oldan, J. D., Anugu, A., Islam, M. Z., Amindarolzarbi, A., Werner, R. A., Pomper, M. G., Solnes, L. B., Almaguel, F., Moschos, S., Viglianti, B. L., & Rowe, S. P. (2025). Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types. Diagnostic and Interventional Imaging. https://doi.org/10.1016/j.diii.2025.07.003

Vancouver

Oldan JD, Anugu A, Islam MZ, Amindarolzarbi A, Werner RA, Pomper MG, et al. Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types. Diagnostic and Interventional Imaging. 2025. doi:10.1016/j.diii.2025.07.003

BibTeX
@article{Oldan2025,
  author = {Oldan, Jorge D and Anugu, Anurag and Islam, Md Zobaer and Amindarolzarbi, Alireza and Werner, Rudolf A and Pomper, Martin G and Solnes, Lilja B and Almaguel, Frankis and Moschos, Stergios and Viglianti, Benjamin L and Rowe, Steven P},
  title = {Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types},
  journal = {Diagnostic and Interventional Imaging},
  year = {2025},
  doi = {10.1016/j.diii.2025.07.003}
}
Kostenlos starten →